CATALIST-LISTED medtech firm Biolidics on Thursday said its Covid-19 antibody test kits had, on Wednesday, obtained authorisation from the Indonesian health authorities for distribution and use in Indonesia.
The authorisation remains valid until Nov 25, 2021. The validity period may be extended "should there be no undesirable events upon usage", Biolidics said.
The company noted that results from the test kits are not to be used for confirmatory testing or as the sole basis for diagnosis. The results have to be interpreted together with clinical presentation and are to be confirmed with supplementary testing.
It said shareholders and potential investors should note that policies relating to the diagnosis and detection of the Covid-19 virus and antibodies in various jurisdictions may change in response to developments in the Covid-19 situation, which is evolving rapidly.
Shares in Biolidics closed at S$0.31 on Thursday, up S$0.01 or 3.33 per cent.